HIMS Quote, Financials, Valuation and Earnings

Grove Collaborative Holdings has a net margin of 5.41% compared to Hims & Hers Health's net margin of -2.77%. Hims & Hers Health's return on equity of 32.03% beat Grove Collaborative Holdings's return on equity of -125.41%.

Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 20.8%. On the other hand Grove Collaborative Holdings has an analysts' consensus of $2.50 which suggests that it could grow by 52.44%. Given that Grove Collaborative Holdings has higher upside potential than Hims & Hers Health, analysts believe Grove Collaborative Holdings is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Grove Collaborative Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Grove Collaborative Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Grove Collaborative Holdings pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are larger than Grove Collaborative Holdings quarterly revenues of $48.3M. Hims & Hers Health's net income of $26M is higher than Grove Collaborative Holdings's net income of -$1.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 66.57x while Grove Collaborative Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 5.76x versus 0.28x for Grove Collaborative Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Kenvue has a net margin of 5.41% compared to Hims & Hers Health's net margin of 8%. Hims & Hers Health's return on equity of 32.03% beat Kenvue's return on equity of 9.84%.

Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 20.8%. On the other hand Kenvue has an analysts' consensus of $23.80 which suggests that it could fall by -0.49%. Given that Hims & Hers Health has higher upside potential than Kenvue, analysts believe Hims & Hers Health is more attractive than Kenvue.

Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Kenvue has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kenvue offers a yield of 3.41% to investors and pays a quarterly dividend of $0.21 per share. Hims & Hers Health pays -- of its earnings as a dividend. Kenvue pays out 150.68% of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are smaller than Kenvue quarterly revenues of $3.7B. Hims & Hers Health's net income of $26M is lower than Kenvue's net income of $293M. Notably, Hims & Hers Health's price-to-earnings ratio is 66.57x while Kenvue's PE ratio is 45.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 5.76x versus 2.98x for Kenvue. Usually stocks with elevated PS ratios are considered overvalued.

The Beauty Health has a net margin of 5.41% compared to Hims & Hers Health's net margin of -23.21%. Hims & Hers Health's return on equity of 32.03% beat The Beauty Health's return on equity of -41.24%.

Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 20.8%. On the other hand The Beauty Health has an analysts' consensus of $1.72 which suggests that it could grow by 33.59%. Given that The Beauty Health has higher upside potential than Hims & Hers Health, analysts believe The Beauty Health is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison The Beauty Health has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Beauty Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. The Beauty Health pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are larger than The Beauty Health quarterly revenues of $78.8M. Hims & Hers Health's net income of $26M is higher than The Beauty Health's net income of -$18.3M. Notably, Hims & Hers Health's price-to-earnings ratio is 66.57x while The Beauty Health's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 5.76x versus 0.50x for The Beauty Health. Usually stocks with elevated PS ratios are considered overvalued.

Waldencast PLC has a net margin of 5.41% compared to Hims & Hers Health's net margin of --. Hims & Hers Health's return on equity of 32.03% beat Waldencast PLC's return on equity of -9.22%.

Hims & Hers Health has a consensus price target of $43.43, signalling upside risk potential of 20.8%. On the other hand Waldencast PLC has an analysts' consensus of $5.76 which suggests that it could grow by 84.62%. Given that Waldencast PLC has higher upside potential than Hims & Hers Health, analysts believe Waldencast PLC is more attractive than Hims & Hers Health.

Hims & Hers Health has a beta of 1.368, which suggesting that the stock is 36.817% more volatile than S&P 500. In comparison Waldencast PLC has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Hims & Hers Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Waldencast PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hims & Hers Health pays -- of its earnings as a dividend. Waldencast PLC pays out -- of its earnings as a dividend.

Hims & Hers Health quarterly revenues are $481.1M, which are larger than Waldencast PLC quarterly revenues of --. Hims & Hers Health's net income of $26M is higher than Waldencast PLC's net income of --. Notably, Hims & Hers Health's price-to-earnings ratio is 66.57x while Waldencast PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hims & Hers Health is 5.76x versus 1.32x for Waldencast PLC. Usually stocks with elevated PS ratios are considered overvalued.